We are live on ! Find out more
WHWK

Whitehawk Therapeutics

65 hedge funds and large institutions have $26.8M invested in Whitehawk Therapeutics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

47% more call options, than puts

Call options by funds: $25K | Put options by funds: $17K

5.89% less ownership

Funds ownership: 60.06%54.16% (-5.9%)

11% less funds holding

Funds holding: 7365 (-8)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

37% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 19

64% less capital invested

Capital invested by funds: $75.3M → $26.8M (-$48.4M)

Holders
65
Holders Change
-8
Holders Change %
-10.96%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
12
Increased
25
Reduced
11
Closed
19
Calls
$25K
Puts
$17K
Net Calls
+$8K
Net Calls Change
-$62K
Name Holding Trade Value Shares
Change
Change in
Stake
AICPI
26
ABG Innovation Capital Partners III
Hong Kong
$53.9K
PCM
27
Prelude Capital Management
New York
$53.3K +$18.9K +4,500 +21%
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$50.1K
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$48.2K +$22.8K +5,433 +29%
Barclays
30
Barclays
United Kingdom
$45K +$81.5K +19,434 +687%
Marshall Wace
31
Marshall Wace
United Kingdom
$43.2K +$89.8K +21,400 New
N
32
Nuveen
North Carolina
$42.2K
Mercer Global Advisors
33
Mercer Global Advisors
Colorado
$37K +$75.9K +18,100 New
UBS Group
34
UBS Group
Switzerland
$35.9K +$36.2K +8,634 +95%
EGM
35
Engineers Gate Manager
New York
$23.1K +$48K +11,452 New
T. Rowe Price Associates
36
T. Rowe Price Associates
Maryland
$22K -$839K -200,000 -95%
JP Morgan Chase
37
JP Morgan Chase
New York
$21.3K
XT
38
XTX Topco
Cayman Islands
$20.7K +$42.9K +10,229 New
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$20.5K -$96 -23 -0.2%
Wells Fargo
40
Wells Fargo
California
$18.3K +$3.03K +723 +9%
AIG
41
American International Group
New York
$16.3K -$134 -32 -0.4%
Ohio Public Employees Retirement System (OPERS)
42
Ohio Public Employees Retirement System (OPERS)
Ohio
$15.8K +$26K +6,200 +388%
SO
43
STRS Ohio
Ohio
$13K +$20.6K +4,900 +288%
PA
44
Parallel Advisors
California
$12.9K -$210 -50 -0.8%
TRCT
45
Tower Research Capital (TRC)
New York
$10.6K -$47.5K -11,330 -68%
Simplex Trading
46
Simplex Trading
Illinois
$9K +$19.6K +4,661 New
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
$8K +$4.64K +1,105 +36%
US Bancorp
48
US Bancorp
Minnesota
$6.73K
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$5.39K -$3.81K -909 -25%
Fidelity Investments
50
Fidelity Investments
Massachusetts
$5.13K +$1.35K +323 +15%

WHWK Hedge Fund Activity: Q4 2023 in Review

65 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2023, worth a combined $26.8M — down 64% from $75.3M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of WHWK and 12 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 25 added.

The largest buyer was Morgan Stanley, adding an estimated $3.37M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $3.78M sold.

  • 65 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2023, down from 73 in Q3 2023.
  • Funds reported $26.8M of Whitehawk Therapeutics stock for Q4 2023, down 64% quarter-over-quarter.
  • 12 funds opened new Whitehawk Therapeutics positions in Q4 2023 and 19 closed out, a net change of -7 holders.
  • The largest Whitehawk Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $3.37M added.
  • The largest Whitehawk Therapeutics seller in Q4 2023 was Janus Henderson Group, an estimated $3.78M sold.

Based on aggregated 13F filings for Q4 2023.